When people living with HIV take antiviral therapy (ART), their viral loads are driven so low that a standard blood test cannot detect the virus.
Monthly Archives: January 2023
Scientists have shown for the first time that briefly tuning into a person’s individual brainwave cycle before they perform a learning task dramatically boosts the speed at which cognitive skills improve.
A new survey finds that men who would be potential users of HIV pre-exposure prophylaxis (PrEP) medication prefer long-acting injections over pills, but rank side effects and costs as the most important issues for them in considering whether to take PrEP.
Stressful experiences during early childhood — particularly economic strife — appear to act as a toxic stressor that can alter regions of the brain tied to the processing of stress and trauma, according to a new study published Wednesday. The researchers found that Black children were impacted more than white children, largely because of the […]
A new study led by scientists at The Neuro (Montreal Neurological Institute-Hospital) of McGill University finds a correlation between neurodegeneration in obese people and Alzheimer’s disease (AD) patients, suggesting that losing excess weight could slow cognitive decline in aging and lower risk for AD.
Compared to other common supplemental screening methods, breast MRI was superior at detecting breast cancer in women with dense breasts, according to a study published in Radiology, a journal of the Radiological Society of North America.
The “Pancreatic ductal adenocarcinoma” (PDAC) is by far the most common form of cancer of the pancreas. PDAC tumors have an extremely poor prognosis because of several reasons.
In our body, we have both an innate immune system and an immune system that is developed throughout life. Part of the innate immune system consists of so-called NK cells.
Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.
Results from the SWOG S1416 clinical trial show that adding veliparib to chemotherapy can significantly extend progression-free survival (PFS) times in patients with triple-negative breast cancer (TNBC) that has a “BRCA-like” phenotype.